Systematic Follow up of Second Line Treatments for Parkinson's Disease (Deep Brain Stimulation, Apomorphin Pump, Duodopa Pump)

Primary purpose: Fluctuations and dyskinesia evolution in Parkinson's disease patients, one year after initiation of deep brain stimulation, apomorphin pump or duodopa pump Secundary purposes: Motor complications evolution at 6 months, 2 and 3 years MDS UPDRS III score at 6 months, 1, 2 and 3 years non motor complications evolution at 6 months, 1, 2 and 3 years cognition and psychiatric complications evolution at 6 months, 1, 2 and 3 years cutaneous and digestive complications at 6 months, 1, 2 and 3 years neuropathy occurrence at 6 months, 1, 2 and 3 years medical treatment and Levodopa equivalent dose modifications at 6 months, 1, 2 and 3 years